Cancer Pain Management Beyond the WHO Ladder: A Modern Mechanism-Based and Interventional Approach

Medically reviewed by Dr. Gautam Das, MD, FIPP — Last Updated on 10th April 2026

Abstract

Cancer pain remains one of the most common and most feared symptoms in oncology. Contemporary evidence shows that pain affects a substantial proportion of patients across the cancer continuum, with particularly high prevalence in advanced disease and palliative settings.[1] Although the World Health Organization (WHO) analgesic ladder remains a historic and practical foundation for cancer pain treatment, modern evidence-based care increasingly requires a broader model that includes mechanism-based diagnosis, repeated structured assessment, adjuvant pharmacotherapy, management of breakthrough pain, psychosocial support, oncologic co-treatment, rehabilitation, and timely interventional pain procedures.[2-4] Neuropathic cancer pain, mixed pain states, refractory visceral pain, and procedure-responsive focal pain syndromes are especially important situations in which a simple stepwise opioid-escalation model may be insufficient.[3,5] In selected patients, interventions such as celiac plexus neurolysis, splanchnic neurolysis, neuraxial analgesia, and intrathecal drug delivery can reduce pain intensity and opioid burden while improving quality of life.[6-8] At Daradia: The Pain Clinic, the concept of cancer pain care has long emphasized going beyond the WHO ladder, and this approach remains highly relevant today.[9-11]

Keywords: cancer pain, WHO analgesic ladder, neuropathic cancer pain, breakthrough cancer pain, interventional pain management, celiac plexus neurolysis, intrathecal pump, palliative care

Introduction

Cancer pain is not a single symptom but a multidimensional clinical syndrome. It may result from tumor invasion, bone destruction, visceral distension, nerve infiltration, treatment-related tissue injury, chemotherapy-induced neuropathy, radiation-related inflammation, surgery, immobility, psychological distress, or combinations of these mechanisms.[3,5] For this reason, cancer pain is often best understood as a biopsychosocial and sometimes total pain experience rather than a purely nociceptive complaint.[3,9]

The older Daradia cancer page correctly emphasized a clinically important point: many patients need treatment beyond the traditional WHO ladder.[9] That message remains valid. However, current literature supports a more precise formulation. The WHO ladder remains useful, but modern cancer pain care should be individualized, mechanism-based, reassessed over time, and expanded to include interventional and supportive strategies whenever indicated.[2-4]

Key Takeaways

Cancer pain remains common across the cancer continuum, with pain affecting a large proportion of patients and moderate-to-severe pain still seen in many cases.
The WHO analgesic ladder is still useful, but many patients need a broader, mechanism-based approach that includes repeated assessment, adjuvant therapy, supportive care, and timely interventional options.
Neuropathic and mixed cancer pain are common and are often under-recognized if treatment focuses only on opioid escalation.
Breakthrough cancer pain should be assessed separately from background pain because it has a major impact on function, sleep, and quality of life.
In selected patients with refractory upper abdominal cancer pain, celiac plexus neurolysis or splanchnic nerve neurolysis may reduce pain and opioid burden.
For severe refractory cancer pain, intrathecal drug delivery systems may be considered when systemic therapy is inadequate or poorly tolerated.

Evidence at a Glance

Topic	What current evidence says	Clinical implication
Prevalence of cancer pain	Cancer pain remains highly prevalent across the cancer continuum, with a significant proportion of patients experiencing moderate-to-severe pain.	Cancer pain should be screened for routinely at every meaningful oncology or pain visit.
Neuropathic or mixed pain	Modern guidance emphasizes identifying whether pain is somatic, visceral, neuropathic, incidental, persistent, or breakthrough rather than treating all cancer pain as a single entity.	Mechanism-based assessment improves treatment selection, especially when adjuvants or interventions may help.
Breakthrough cancer pain	Breakthrough, persistent, and incidental pain are distinct clinical patterns and should be recognized separately.	Do not assume background opioid treatment alone is enough; assess pain flares separately and treat them specifically.
Celiac plexus neurolysis / splanchnic neurolysis	Neurolytic procedures can help selected patients with upper abdominal cancer pain and may reduce both pain severity and opioid burden.	Consider referral for image-guided intervention when upper abdominal visceral pain is severe, focal, and opioid-limited or refractory.
Intrathecal therapy	Intrathecal drug delivery systems can be an effective option for selected patients with refractory cancer pain.	Consider intrathecal therapy in carefully selected patients with refractory pain or unacceptable systemic opioid toxicity.

Prevalence of Cancer Pain

Pain continues to be a major burden in cancer care. A 2023 systematic review and meta-analysis reported that the overall prevalence of pain in patients with cancer was 44.5%, while 30.6% experienced moderate-to-severe pain.[1] Pain prevalence remains especially high in patients with advanced, metastatic, and palliative-stage disease.[1,3] These contemporary estimates broadly support the clinical concern reflected in the original Daradia page, while providing a more up-to-date evidence base for scholarly presentation.[1,9]

Cancer pain also has a substantial effect on emotional well-being, sleep, daily activity, and function. The National Cancer Institute PDQ states that cancer pain is associated with increased emotional distress, and both pain severity and duration correlate with a greater risk of depression.[3] Persistent uncontrolled pain also contributes to functional limitation, healthcare use, and poorer quality of life.[3]

Types of Cancer Pain

Nociceptive pain

Nociceptive cancer pain arises from activation of pain-sensitive structures by tissue injury, inflammation, stretch, or compression. It may be somatic, as in bone metastasis or chest wall infiltration, or visceral, as in pancreatic, hepatobiliary, retroperitoneal, pelvic, or bowel-related malignancy.[3,5] Somatic pain is often better localized, whereas visceral pain is more diffuse and may be associated with autonomic symptoms.[3]

Neuropathic cancer pain

Neuropathic cancer pain results from disease- or treatment-related injury to the somatosensory nervous system. It may occur because of direct tumor infiltration, nerve compression, plexopathy, chemotherapy, radiotherapy, or post-surgical neural injury.[3,5] A recent review notes that neuropathic cancer pain affects approximately 30% to 40% of patients with cancer and is associated with worse quality of life, greater complexity of treatment, and a higher likelihood of mixed pain mechanisms.[5] This is especially important because neuropathic pain is often undertreated if clinicians rely only on opioid escalation without mechanism-based assessment.[5]

Mixed pain

In many patients, cancer pain is mixed rather than purely nociceptive or purely neuropathic.[5] This has major therapeutic implications, because mixed pain often requires a combination of opioid analgesia, adjuvant analgesics, disease-directed treatment, and in some cases targeted intervention.[3-5]

Treatment of Cancer Pain With the WHO Ladder

The WHO introduced the analgesic ladder in 1986 as a simple stepwise framework for cancer pain treatment.[2] The traditional three-step model begins with non-opioids for mild pain, then weak opioids for mild-to-moderate pain, and strong opioids for moderate-to-severe pain, with adjuvants added as needed.[2] The WHO model played a transformative role in global cancer pain care by making treatment more systematic and more accessible.[2]

Even today, the ladder remains clinically useful as an organizing principle, especially where cancer pain management is inconsistent or under-structured.[2-4] However, contemporary guidelines have moved beyond a narrow ladder-only approach. The 2025 NCCN Adult Cancer Pain guideline emphasizes comprehensive pain screening, reassessment, safe opioid prescribing, nonpharmacologic methods, integrative strategies, and interventional options as part of routine cancer pain care.[4] Similarly, the NCI PDQ stresses regular screening, detailed characterization of pain type and mechanism, individualized treatment, and repeated reassessment rather than one-time stepwise prescribing alone.[3]

Thus, the WHO ladder should now be seen as a foundation, not as the full architecture of cancer pain management.[2-4]

WHO ladde with 4th step — WHO Ladder with 4th step

Under-Treatment of Cancer Pain

Despite decades of guidelines, under-treatment remains common. A contemporary review on neuropathic cancer pain notes that at least one-third of patients with cancer pain are undertreated, often because of inadequate attention to pain during routine oncology encounters.[5] Earlier systematic work on undertreatment also showed persistent inadequacy of cancer pain management across settings and countries, despite availability of analgesics and growing clinical knowledge.[12]

This gap matters clinically because uncontrolled cancer pain is not merely uncomfortable; it worsens function, mood, sleep, mobility, participation in treatment, and overall quality of life.[3,5,12] It may also push clinicians toward repeated unsystematic medication changes rather than mechanism-based correction of the pain strategy.[3,4]

Barriers in Cancer Pain Management

Barriers to effective cancer pain control remain multidimensional. They can be grouped into system barriers, clinician barriers, and patient barriers.[5,12]

System barriers include poor prioritization of pain treatment, limited access to palliative care and pain specialists, inadequate institutional pathways, and legal or regulatory obstacles affecting opioid availability.[2,12] Clinician barriers include inadequate pain assessment, insufficient familiarity with opioid conversion, fear of adverse effects, underuse of adjuvant drugs, failure to recognize neuropathic or breakthrough pain, and delayed referral for interventions.[3-5] Patient barriers include fear of opioids, stigma, poor reporting of pain, misconceptions that pain is inevitable, and concerns about addiction, sedation, or disease progression.[12]

These barriers explain why some patients remain undertreated even when analgesics are technically available.[5,12]

Why Cancer Pain Management Must Go Beyond the WHO Ladder

The original Daradia page highlighted the limitations of the WHO ladder and the need for a broader approach.[9] That argument remains sound for several reasons.

First, the ladder does not by itself solve the problem of mixed-mechanism pain, especially when neuropathic, visceral, inflammatory, incident, and breakthrough pain coexist.[3-5] Second, some focal pain syndromes are anatomically suitable for intervention and may respond better to targeted procedures than to continued systemic dose escalation.[6,7] Third, contemporary guidelines now explicitly incorporate interventional, integrative, and nonpharmacologic strategies as part of standard adult cancer pain care rather than as niche or last-minute options.[4]

The modern view is therefore not that the WHO ladder is obsolete, but that it is incomplete when used in isolation.[2-4]

Modalities of Modern Cancer Pain Management

Cancer pain management should be multimodal and individualized.[3,4]

1. Pharmacological therapy

Pharmacologic treatment remains central. Depending on pain severity and mechanism, treatment may include paracetamol, nonsteroidal anti-inflammatory drugs where appropriate, strong opioids, corticosteroids, antidepressants, anticonvulsants, topical agents in selected cases, and drugs targeted to specific mechanisms such as bone pain or neuropathic pain.[2-5] Adjuvant analgesics are particularly important in neuropathic cancer pain and mixed pain states.[5]

2. Assessment and reassessment

Repeated standardized pain assessment is not optional; it is core treatment. The NCI PDQ and recent guideline literature emphasize that pain should be assessed at every meaningful patient contact, including site, severity, mechanism, temporal pattern, breakthrough episodes, sleep effect, and functional impact.[3,5] Better assessment leads to better targeting of therapy.

3. Psychological and supportive care

Because cancer pain is intertwined with distress, fear, sleep disturbance, and social suffering, psychological support and palliative care integration are important parts of treatment.[3] The concept of “total pain” remains clinically useful in reminding clinicians that analgesic escalation alone may not control suffering.[3,9]

4. Oncologic and rehabilitative treatment

Disease-directed measures such as radiotherapy, systemic anticancer therapy, surgery, and supportive rehabilitation may significantly reduce pain in appropriate patients.[2-4] For example, radiation can be an important component of pain control in bone metastasis, although transient pain flare may occur and should be anticipated.[3]

5. Interventional pain management

Interventional procedures are especially relevant in selected patients with focal, refractory, anatomically targetable, opioid-limiting, or opioid-refractory pain syndromes.[4,6-8] This is the area where the “beyond WHO ladder” concept is most clinically meaningful.

Breakthrough Cancer Pain

Breakthrough cancer pain is a transient exacerbation of pain occurring despite relatively controlled background pain.[3,13] It is clinically important because it worsens mobility, sleep, confidence, function, and quality of life, and because it is frequently under-recognized unless directly asked about.[3,13] Assessment should distinguish background pain from end-of-dose failure, incident pain, procedure-related pain, and spontaneous breakthrough episodes.[3,13]

Modern management requires optimization of baseline analgesia, identification of trigger patterns, and use of rescue strategies suited to the temporal profile of the pain episode.[3,13] Failure to document and treat breakthrough pain is one reason patients may appear “opioid resistant” when the real problem is incomplete pain characterization.[3,9]

Interventional Pain Management in Cancer Pain

The role of interventional pain management in cancer pain is now better supported than when many older web pages were first written. Contemporary guidance increasingly recognizes that interventional options should be considered for selected patients with refractory pain, intolerable opioid toxicity, or pain syndromes with clear anatomical targets.[4,6-8]

Neurolytic procedures

Neurolytic procedures remain important in upper abdominal and pelvic malignancy-related pain. Celiac plexus neurolysis has long been used for upper abdominal cancer pain, particularly pancreatic and related malignancies.[6,7] A 2022 systematic review and meta-analysis found evidence supporting celiac plexus neurolysis for abdominal cancer pain, particularly at short-term follow-up.[6] A more recent 2024 meta-analysis comparing celiac plexus neurolysis and splanchnic nerve neurolysis evaluated pain, opioid consumption, complications, quality of life, and survival in upper abdominal cancer pain, underscoring the continuing relevance of these procedures in appropriately selected patients.[7]

Daradia’s own site reflects this clinical emphasis through dedicated educational resources on Celiac Plexus Block and USG-guided Celiac Plexus Block/Neurolysis for Abdominal Pain.[10,11]

Neuraxial and intrathecal strategies

For severe refractory cancer pain, neuraxial drug delivery may be appropriate in selected patients, especially when systemic opioid escalation produces inadequate relief or unacceptable adverse effects.[4,8] A 2024 health technology assessment concluded that intrathecal drug delivery systems can be an effective treatment option for cancer pain, though patient selection, cost, prognosis, and service availability remain important considerations.[8]

Daradia also maintains a dedicated patient-facing resource on the Intrathecal Pump, which aligns with this advanced tier of cancer pain care.[14]

When should intervention be considered?

Interventions may be especially worth considering when pain is relatively well localized, anatomically targetable, associated with upper abdominal or pelvic malignancy, refractory to optimized drug treatment, limited by opioid adverse effects, or when reduction of systemic opioid burden is an important clinical goal.[4,6-8] This modern interpretation strongly supports the long-standing clinical argument on Daradia’s cancer page that some patients do better when treatment moves beyond exclusive ladder-based pharmacotherapy.[9]

A Practical Contemporary Framework

A contemporary cancer pain strategy should proceed through the following sequence:[3-5]

Screen for pain routinely.
Characterize the pain carefully by mechanism, site, intensity, temporality, and impact.
Distinguish background pain from breakthrough pain.
Identify neuropathic and mixed mechanisms early.
Treat with multimodal pharmacology, not opioid escalation alone.
Integrate oncologic, rehabilitative, psychological, and palliative care measures.
Refer for image-guided intervention when pain is focal, refractory, or anatomically suitable.

This approach is consistent with current guideline thinking and better reflects real-world cancer pain practice than a rigid three-step escalation model alone.[3-5]

Conclusion

Cancer pain remains highly prevalent, clinically heterogeneous, and frequently undertreated.[1,5,12] The WHO ladder still matters, but modern cancer pain care should not stop there.[2-4] Neuropathic cancer pain, mixed pain syndromes, breakthrough pain, focal visceral pain, and opioid-limiting toxicity all demand a broader, mechanism-based, multimodal strategy.[3-5] In selected patients, interventional procedures such as celiac plexus neurolysis, splanchnic neurolysis, neuraxial analgesia, and intrathecal drug delivery can play a decisive role in improving pain control and quality of life.[6-8] Therefore, the most defensible contemporary position is clear: effective cancer pain management often requires going beyond the WHO ladder.[4,6-9]

References

Snijders RAH, Brom L, Theunissen M, van den Beuken-van Everdingen MHJ. Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers (Basel). 2023;15(3):591.
World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization; 2019.
National Cancer Institute. Cancer Pain (PDQ®)–Health Professional Version. Bethesda (MD): National Cancer Institute; updated 2025 Apr 24.
Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, et al. Adult cancer pain, version 2.2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2025;23(7):e250032.
Mulvey MR, Boland EG, Fallon MT. Neuropathic pain in cancer: what are the current guidelines? Curr Treat Options Oncol. 2024;25:1193-1202.
Okita M, Kato K, Takahashi M, Ouchi T, Inoue M, Ibusuki M, et al. Systematic review and meta-analysis of celiac plexus neurolysis for abdominal pain associated with unresectable pancreatic cancer. Pain Pract. 2022;22(7):652-664.
Wang RR, Wang Q, He Y, Zhou H, Li T, Liu D. Efficacy and safety of celiac plexus neurolysis versus splanchnic nerve neurolysis for upper abdominal cancer pain: a systematic review and meta-analysis. Pain Physician. 2024;27:E937-E947.
Ontario Health. Intrathecal drug delivery systems for cancer pain: a health technology assessment. Ont Health Technol Assess Ser. 2024;24(2):1-176.
Daradia: The Pain Clinic. Cancer Pain Management – Beyond WHO Ladder. Kolkata: Daradia: The Pain Clinic. Available from: https://daradia.com/cancer/
Daradia: The Pain Clinic. Celiac Plexus Block: C-Arm Guided Transaortic Approach. Kolkata: Daradia: The Pain Clinic. Available from: https://daradia.com/celiac-plexus-block/
Daradia: The Pain Clinic. USG-Guided Celiac Plexus Block/Neurolysis for Abdominal Pain. Kolkata: Daradia: The Pain Clinic. Available from: https://daradia.com/usg-guided-celiac-plexus-block/
Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol. 2014;32(36):4149-4154.
Yeo J, Chang YJ. Breakthrough pain and rapid-onset opioids in patients with cancer pain: a narrative review. Yeungnam Univ J Med. 2024;41(1):1-10.
Daradia: The Pain Clinic. Intrathecal Pump. Kolkata: Daradia: The Pain Clinic. Available from: https://daradia.com/intrathecal-pump/

Frequently Asked Questions

What is cancer pain?

Cancer pain is pain caused by the cancer itself, cancer treatment, or related complications. It may be somatic, visceral, neuropathic, or mixed, and it can affect function, sleep, mood, and quality of life.

Is the WHO pain ladder still used in cancer pain treatment?

Yes. The WHO analgesic ladder is still an important foundation for cancer pain treatment. However, many patients need a broader approach that includes adjuvant medicines, management of breakthrough pain, supportive care, radiotherapy, rehabilitation, and interventional pain procedures.

Why does cancer pain treatment sometimes go beyond medicines alone?

Some cancer pain is refractory, mixed in mechanism, or associated with intolerable side effects from systemic opioids. In such cases, targeted interventions such as celiac plexus neurolysis, splanchnic neurolysis, neuraxial analgesia, or intrathecal therapy may help reduce pain and opioid burden.

What is breakthrough cancer pain?

Breakthrough cancer pain is a temporary flare of severe pain that occurs despite relatively controlled background pain. It needs separate assessment and treatment because it can significantly affect activity, sleep, and quality of life.

Can neuropathic pain occur in cancer patients?

Yes. Neuropathic cancer pain can occur due to tumor infiltration, nerve compression, chemotherapy, radiotherapy, or surgery. It often needs mechanism-based treatment, including adjuvant analgesics and sometimes interventional options.

What interventional procedures are used for cancer pain?

Depending on the pain pattern and underlying disease, interventional options may include celiac plexus neurolysis, splanchnic nerve neurolysis, nerve blocks, neuraxial analgesia, vertebral augmentation, or intrathecal drug delivery systems.

When should a cancer patient be referred to a pain specialist?

Referral should be considered when pain remains uncontrolled, when opioid side effects limit treatment, when the pain has neuropathic or mixed features, when breakthrough pain is frequent, or when an image-guided intervention may be useful.

Does Daradia treat cancer pain?

Daradia: The Pain Clinic provides pain medicine evaluation and interventional pain management options for selected patients with cancer pain, including advanced pain procedures when clinically appropriate.

Medically reviewed by Dr. Gautam Das and Daradia Pain Team

Last updated on: 10th April 2026

Update on Cancer Pain Management